SG10201808312YA - Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines - Google Patents
Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccinesInfo
- Publication number
- SG10201808312YA SG10201808312YA SG10201808312YA SG10201808312YA SG10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA
- Authority
- SG
- Singapore
- Prior art keywords
- aluminum salt
- enhancing
- methods
- adsorbed
- immunostimulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16271—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
METHODS FOR ENHANCING THE IMMUNOSTIMULATION POTENCY OF ALUMINUM SALT-ADSORBED VACCINES Provided herein are (1) a method of mixing an aluminum salt-adsorbed immunogen with a monophosphoryl lipid A (MPLA)-containing liposome (L(MPLA)), and (2) the resulting immunogenic composition. The resulting immunogenic composition has an enhanced immunostimulation potency compared with either a composition comprising the uncapsulated immunogen mixed with the L(MPLA) or the aluminum salt-adsorbed immunogen alone. (FIG. 1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461969905P | 2014-03-25 | 2014-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201808312YA true SG10201808312YA (en) | 2018-10-30 |
Family
ID=51302762
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201808312YA SG10201808312YA (en) | 2014-03-25 | 2014-07-09 | Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines |
SG11201607404PA SG11201607404PA (en) | 2014-03-25 | 2014-07-09 | Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201607404PA SG11201607404PA (en) | 2014-03-25 | 2014-07-09 | Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines |
Country Status (12)
Country | Link |
---|---|
US (1) | US20170165358A1 (en) |
EP (1) | EP3122379A1 (en) |
JP (1) | JP2017509713A (en) |
KR (1) | KR20170016315A (en) |
CN (1) | CN106535929A (en) |
AU (1) | AU2014388299A1 (en) |
BR (1) | BR112016021692A2 (en) |
CA (1) | CA2943050A1 (en) |
MX (1) | MX2016012166A (en) |
RU (1) | RU2016141621A (en) |
SG (2) | SG10201808312YA (en) |
WO (1) | WO2015147899A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6918365B2 (en) | 2015-08-19 | 2021-08-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Lipidized PSA Compositions and Methods |
WO2018014012A1 (en) * | 2016-07-15 | 2018-01-18 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
JP7385206B2 (en) | 2018-12-04 | 2023-11-22 | 国立大学法人大阪大学 | immunostimulant |
WO2022019665A1 (en) * | 2020-07-22 | 2022-01-27 | (주)쓰리에이치바이오 | Peptide for immunotherapeutic agent |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1124013A (en) * | 1993-02-19 | 1996-06-05 | 史密丝克莱恩比彻姆公司 | Influenza vaccine compositions containing 3-O-deacylated monophosphoryl lipid a |
WO1994019013A1 (en) * | 1993-02-19 | 1994-09-01 | Smithkline Beecham Corporation | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
ATE204762T1 (en) * | 1993-03-23 | 2001-09-15 | Smithkline Beecham Biolog | VACCINE COMPOSITIONS CONTAINING 3-0-DEAZYLATED MONOPHOSPHORYL LIPID A |
NZ560930A (en) * | 2005-02-16 | 2011-06-30 | Novartis Vaccines & Diagnostic | Hepatitis B virus vaccine comprising a hepatitis B virus surface antigen, aluminium phosphate, 3-O-deacylated monophosphoryl lipid A and a triethylammonium ion |
EA018201B1 (en) * | 2007-05-24 | 2013-06-28 | Глаксосмитклайн Байолоджикалс С.А. | Lyophilised antigen composition |
WO2011117408A1 (en) * | 2010-03-26 | 2011-09-29 | Glaxosmithkline Biologicals S.A. | Hiv vaccine |
-
2014
- 2014-07-09 MX MX2016012166A patent/MX2016012166A/en unknown
- 2014-07-09 RU RU2016141621A patent/RU2016141621A/en not_active Application Discontinuation
- 2014-07-09 AU AU2014388299A patent/AU2014388299A1/en not_active Abandoned
- 2014-07-09 KR KR1020167025974A patent/KR20170016315A/en not_active Application Discontinuation
- 2014-07-09 SG SG10201808312YA patent/SG10201808312YA/en unknown
- 2014-07-09 US US15/127,076 patent/US20170165358A1/en not_active Abandoned
- 2014-07-09 SG SG11201607404PA patent/SG11201607404PA/en unknown
- 2014-07-09 BR BR112016021692A patent/BR112016021692A2/en not_active Application Discontinuation
- 2014-07-09 JP JP2017502571A patent/JP2017509713A/en active Pending
- 2014-07-09 WO PCT/US2014/045940 patent/WO2015147899A1/en active Application Filing
- 2014-07-09 CA CA2943050A patent/CA2943050A1/en not_active Abandoned
- 2014-07-09 EP EP14750386.6A patent/EP3122379A1/en not_active Withdrawn
- 2014-07-09 CN CN201480077507.5A patent/CN106535929A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2016141621A (en) | 2018-04-25 |
CA2943050A1 (en) | 2015-10-01 |
MX2016012166A (en) | 2017-03-15 |
RU2016141621A3 (en) | 2018-05-11 |
AU2014388299A1 (en) | 2016-10-20 |
SG11201607404PA (en) | 2016-10-28 |
BR112016021692A2 (en) | 2017-08-15 |
JP2017509713A (en) | 2017-04-06 |
WO2015147899A1 (en) | 2015-10-01 |
KR20170016315A (en) | 2017-02-13 |
CN106535929A (en) | 2017-03-22 |
US20170165358A1 (en) | 2017-06-15 |
EP3122379A1 (en) | 2017-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3416679A4 (en) | Pathogen vaccines and methods of producing and using the same | |
PH12018500947B1 (en) | Crystal form, preparation method and intermediate of dihydropyrido ring compound | |
PH12017500762A1 (en) | Proflavor delivery particles | |
EP3484448A4 (en) | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same | |
EP3484508A4 (en) | Compositions and methods for alphavirus vaccination | |
EP3413926A4 (en) | Hiv vaccination and immunotherapy | |
SG11202003800YA (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
EP3207142A4 (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
EP3463450A4 (en) | Compositions and methods for tumor vaccination using prostate cancer-associated antigens | |
EP3717511A4 (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
MY191539A (en) | Streptococcal vaccine | |
HK1255559A1 (en) | Mg53 mutant, and preparation method therefor and uses thereof | |
EP3118204A4 (en) | O-phenyl chalcone compound and preparation method and use thereof | |
MX2022013912A (en) | Novel methods for inducing an immune response. | |
EP3600396A4 (en) | Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines | |
EP3075393A4 (en) | Adjuvant composition, vaccine composition comprising same, and method for producing same | |
EP3454891A4 (en) | Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration | |
EP3112351A4 (en) | Naphthylamide compound, preparation method and use thereof | |
SG10201808312YA (en) | Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines | |
EP3429283A4 (en) | Method and device for nan device to send sync beacon message | |
EP3241824A4 (en) | Trifluoroacethydrazide compound as well as preparation method therefor and application thereof in preparing medicament | |
EP3730620A4 (en) | Cross-immunizing antigen vaccine and method for preparation thereof | |
EP3630172A4 (en) | Compositions and methods for tumor vaccination and immunotherapy involving her antigens | |
EP3543248A4 (en) | PHOSPHORESCENT PtAg2 COMPLEX, PREPARATION METHOD THEREFOR AND USE THEREOF | |
EP3357927A4 (en) | Aerogel precursor, preparation method therefor, aerogel prepared therefrom, and aerogel preparation method using same |